Biogen, AbbVie hit with Zinbryta safety action in EU as MS market heats up
admin 10th July 2017 Uncategorised 0Biogen and AbbVie’s multiple sclerosis drug Zinbryta faces new prescribing restrictions in Europe after regulators there reviewed liver injuries and one death in patients taking the medication. It’s a setback at a crucial time, when tough payers and new challengers—including Roche’s Ocrevus—are roiling the MS field.
More: Biogen, AbbVie hit with Zinbryta safety action in EU as MS market heats up
Source: fierce